Literature DB >> 19276373

microRNA-205 regulates HER3 in human breast cancer.

Marilena V Iorio1, Patrizia Casalini, Claudia Piovan, Gianpiero Di Leva, Andrea Merlo, Tiziana Triulzi, Sylvie Ménard, Carlo M Croce, Elda Tagliabue.   

Abstract

An increasing amount of experimental evidence shows that microRNAs can have a causal role in breast cancer tumorigenesis as a novel class of oncogenes or tumor suppressor genes, depending on the targets they regulate. HER2 overexpression is a hallmark of a particularly aggressive subset of breast tumors, and its activation is strictly dependent on the trans-interaction with other members of HER family; in particular, the activation of the PI3K/Akt survival pathway, so critically important in tumorigenesis, is predominantly driven through phosphorylation of the kinase-inactive member HER3. Here, we show that miR-205, down-modulated in breast tumors compared with normal breast tissue, directly targets HER3 receptor, and inhibits the activation of the downstream mediator Akt. The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity. Our data describe miR-205 as a new oncosuppressor gene in breast cancer, able to interfere with the proliferative pathway mediated by HER receptor family. Our study also provides experimental evidence suggesting that miR-205 can improve the responsiveness to specific anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276373     DOI: 10.1158/0008-5472.CAN-08-2920

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  151 in total

Review 1.  Micro-RNAs and breast cancer.

Authors:  John Le Quesne; Carlos Caldas
Journal:  Mol Oncol       Date:  2010-04-28       Impact factor: 6.603

2.  MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2.

Authors:  Jia Yu; Han Peng; Qing Ruan; Anees Fatima; Spiro Getsios; Robert M Lavker
Journal:  FASEB J       Date:  2010-06-07       Impact factor: 5.191

3.  A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer.

Authors:  Aldema Sas-Chen; Roi Avraham; Yosef Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-12       Impact factor: 2.673

4.  Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells.

Authors:  Xiao-Yan Wang; Ming-Hua Wu; Fen Liu; Yu Li; Nan Li; Gui-Yuan Li; Shou-Rong Shen
Journal:  Mol Cell Biochem       Date:  2010-09-22       Impact factor: 3.396

Review 5.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

Review 6.  microRNAs and EMT in mammary cells and breast cancer.

Authors:  Josephine A Wright; Jennifer K Richer; Gregory J Goodall
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-25       Impact factor: 2.673

Review 7.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 8.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

9.  Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments.

Authors:  Nicole Guzman; Kitty Agarwal; Dilip Asthagiri; Lianbo Yu; Motoyasu Saji; Matthew D Ringel; Michael E Paulaitis
Journal:  Mol Cancer Res       Date:  2015-02-26       Impact factor: 5.852

Review 10.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.